VOR BIOPHARMA INC (VOR) Fundamental Analysis & Valuation
NASDAQ:VOR • US9290332074
Current stock price
18.05 USD
+0.66 (+3.8%)
At close:
18.27 USD
+0.22 (+1.22%)
After Hours:
This VOR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. VOR Profitability Analysis
1.1 Basic Checks
- In the past year VOR has reported negative net income.
- VOR had a negative operating cash flow in the past year.
- VOR had negative earnings in each of the past 5 years.
- VOR had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- VOR's Return On Assets of -1389.92% is on the low side compared to the rest of the industry. VOR is outperformed by 95.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1389.92% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-57.36%
ROA(5y)-53.18%
ROE(3y)-78.63%
ROE(5y)-74.06%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- VOR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. VOR Health Analysis
2.1 Basic Checks
- VOR has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, VOR has more shares outstanding
- There is no outstanding debt for VOR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- VOR has an Altman-Z score of -28.49. This is a bad value and indicates that VOR is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -28.49, VOR is doing worse than 88.01% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -28.49 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 9.16 indicates that VOR has no problem at all paying its short term obligations.
- VOR has a Current ratio of 9.16. This is in the better half of the industry: VOR outperforms 77.37% of its industry peers.
- VOR has a Quick Ratio of 9.16. This indicates that VOR is financially healthy and has no problem in meeting its short term obligations.
- VOR has a better Quick ratio (9.16) than 77.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.16 | ||
| Quick Ratio | 9.16 |
3. VOR Growth Analysis
3.1 Past
- VOR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -85.24%.
EPS 1Y (TTM)-85.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- VOR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.21% yearly.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-278.79%
EPS Next 2Y35.57%
EPS Next 3Y22.56%
EPS Next 5Y14.21%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. VOR Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for VOR. In the last year negative earnings were reported.
- Also next year VOR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as VOR's earnings are expected to grow with 22.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.57%
EPS Next 3Y22.56%
5. VOR Dividend Analysis
5.1 Amount
- VOR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
VOR Fundamentals: All Metrics, Ratios and Statistics
18.05
+0.66 (+3.8%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-18 2026-03-18/amc
Earnings (Next)05-12 2026-05-12
Inst Owners55.44%
Inst Owner Change566.28%
Ins Owners0.01%
Ins Owner Change-29.13%
Market Cap749.44M
Revenue(TTM)N/A
Net Income(TTM)-2.45B
Analysts83.64
Price Target38.18 (111.52%)
Short Float %9.31%
Short Ratio3.86
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-197.99%
Min EPS beat(2)-394.6%
Max EPS beat(2)-1.38%
EPS beat(4)0
Avg EPS beat(4)-115.27%
Min EPS beat(4)-394.6%
Max EPS beat(4)-1.38%
EPS beat(8)3
Avg EPS beat(8)-56.4%
EPS beat(12)4
Avg EPS beat(12)-37.86%
EPS beat(16)6
Avg EPS beat(16)-27.88%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.2%
PT rev (3m)-7.81%
EPS NQ rev (1m)-2.26%
EPS NQ rev (3m)9.43%
EPS NY rev (1m)0%
EPS NY rev (3m)-16.2%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-61.13
EYN/A
EPS(NY)-5.51
Fwd EYN/A
FCF(TTM)-3.48
FCFYN/A
OCF(TTM)-3.47
OCFYN/A
SpS0
BVpS-53.6
TBVpS-53.6
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1389.92% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-57.36%
ROA(5y)-53.18%
ROE(3y)-78.63%
ROE(5y)-74.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 18.75% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 9.16 | ||
| Quick Ratio | 9.16 | ||
| Altman-Z | -28.49 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)123.83%
Cap/Depr(5y)265.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-85.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.38%
EPS Next Y-278.79%
EPS Next 2Y35.57%
EPS Next 3Y22.56%
EPS Next 5Y14.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-211.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-207.98%
EBIT Next 3Y-22.64%
EBIT Next 5YN/A
FCF growth 1Y-50.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-52.18%
OCF growth 3YN/A
OCF growth 5YN/A
VOR BIOPHARMA INC / VOR Fundamental Analysis FAQ
What is the fundamental rating for VOR stock?
ChartMill assigns a fundamental rating of 1 / 10 to VOR.
What is the valuation status for VOR stock?
ChartMill assigns a valuation rating of 1 / 10 to VOR BIOPHARMA INC (VOR). This can be considered as Overvalued.
What is the profitability of VOR stock?
VOR BIOPHARMA INC (VOR) has a profitability rating of 0 / 10.
What is the expected EPS growth for VOR BIOPHARMA INC (VOR) stock?
The Earnings per Share (EPS) of VOR BIOPHARMA INC (VOR) is expected to decline by -278.79% in the next year.